Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Enzyme-linked Receptors

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Transducer Mechanism: Enzyme-Linked Receptors

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

Adrenergic Agonists: Indirect-Acting Agents

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SARM1 base-exchange inhibitors induce SARM1 activation and neurodegeneration at low doses.

npj drug discovery·2026

Same author

An integrated experimental and computational pipeline for crystallographic fragment screening of membrane protein in the lipid cubic phase.

Communications chemistry·2026

Same author

Engineering of acidic pH-responsive anti-CD3 binding antibodies.

mAbs·2026

Same author

Refining the root-associated microbial consortia for enhanced biocontrol of the root-rot pathogen of corn.

Frontiers in microbiology·2026

Same author

Structural Mechanism of an Efficacy Photoswitch Targeting the β<sub>2</sub>-adrenergic Receptor.

Angewandte Chemie (International ed. in English)·2026

Same author

Discovery of Potent and Efficacious Influenza PB2 Inhibitors.

ACS medicinal chemistry letters·2026

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Tyramine fragment binding to BACE-1.

Andreas Kuglstatter¹, Martin Stahl, Jens-Uwe Peters

¹F. Hoffmann-La Roche, Pharma Research Basel, Grenzacherstr., 4070 Basel, Switzerland.

Bioorganic & Medicinal Chemistry Letters

|January 30, 2008

Summary

Researchers discovered tyramine binds to the Alzheimer's target BACE-1. Derivatives showed improved binding, offering starting points for new drug leads against Alzheimer's disease.

More Related Videos

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

Related Experiment Videos

Last Updated: Jul 7, 2026

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

Area of Science:

Biochemistry
Neuroscience
Medicinal Chemistry

Background:

Alzheimer's disease poses a significant global health challenge.
Beta-secretase 1 (BACE-1) is a validated drug target for Alzheimer's disease therapeutics.
Fragment-based drug discovery is a key strategy for identifying novel therapeutic agents.

Purpose of the Study:

To identify small molecules that bind to the active site of BACE-1.
To explore the binding interactions of identified fragments with BACE-1.
To initiate structure-guided design of potential Alzheimer's disease drug leads.

Main Methods:

Fragment screening using biophysical methods.
Hit expansion using a compound library.
Surface plasmon resonance (SPR) for binding affinity measurements.
X-ray crystallography for structural analysis.

Main Results:

Tyramine was identified as a BACE-1 binder.
Tyramine derivatives demonstrated enhanced binding affinities to BACE-1.
X-ray structures revealed hydrogen bonding of the tyramine amine to the catalytic water molecule.
Low molecular weight compounds were synthesized based on structural insights.

Conclusions:

Tyramine is a viable fragment for BACE-1 inhibitor development.
Structure-based design can yield potent BACE-1 inhibitors.
The identified compounds represent promising starting points for Alzheimer's drug discovery.